Kalnik Matthew W. 4
4 · NABI BIOPHARMACEUTICALS · Filed Mar 17, 2010
Insider Transaction Report
Form 4
Kalnik Matthew W.
SVP Strategic Plan. & Bus. Ops
Transactions
- Sale
Common Stock
2010-03-11$5.95/sh−1,125$6,694→ 39,523.104 total - Exercise/Conversion
Stock Option (Right to Buy)
2010-03-11−1,125→ 14,625 totalExercise: $3.95Exp: 2015-04-01→ Common Stock (1,125 underlying) - Exercise/Conversion
Common Stock
2010-03-11$3.95/sh+1,125$4,444→ 40,648.104 total
Footnotes (2)
- [F1]The acquisition and sale of 1,125 shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The Option will become exercisable in four equal annual installments. The first installment vested on April 1, 2009. The remaining installments vest on April 1, 2010, April 1, 2011 and April 1, 2012.